Renalytix AI plc (LSE AIM: RENX) is a leading developer of artificial intelligence-enabled clinical diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company’s solutions are being designed to make significant improvements in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. RenalytixAI’s initial diagnostic product, KidneyIntelX™, is designed to diagnose and improve clinical management of patients with Type II diabetes and those of African ancestry with fast-progressing kidney disease in an effort to curtail the estimated $114 billion cost of chronic and end-stage kidney disease to the U.S. healthcare system. RenalytixAI expects to commercially launch KidneyIntelX as a laboratory developed test in its CLIA laboratory facilities to health systems and drug developers in H2 2019.
Total Funding: $46.4M
Funding Stage: Pre-IPO
Business Stage: Scaling Up
Market: B2C, B2B
Company Size: 26 to 50
Founded: 2018
